key: cord-1045687-p6j049j0
authors: Méndez‐Flores, Silvia; Priego‐Ranero, Ángel; Azamar‐Llamas, Daniel; Olvera‐Prado, Héctor; Rivas‐Redonda, Kenia Ilian; Ochoa‐Hein, Eric; Perez‐Ortiz, Andric; Rendón‐Macías, Mario E.; Rojas‐Castañeda, Estefano; Urbina‐Terán, Said; Septién‐Stute, Luis; Hernández‐Gilsoul, Thierry; Aguilar‐Morgan, Adrián Andrés; Fernández‐Camargo, Dheni A.; Olivares‐Martínez, Elizabeth; Hernández‐Ramírez, Diego F.; Torres‐Villalobos, Gonzalo; Furuzawa‐Carballeda, Janette
title: Effect of polymerised type I collagen on hyperinflammation of adult outpatients with symptomatic COVID‐19
date: 2022-03-16
journal: Clin Transl Med
DOI: 10.1002/ctm2.763
sha: efd3fcbc31459a78149995047c2a343282b509d1
doc_id: 1045687
cord_uid: p6j049j0

nan

placebo groups, respectively. No patients were treated with anticoagulants or steroids.

On day 1 after the last PTIC or placebo administration, the IP-10 levels decreased 75% in the PTIC group (p < .001) and 40% in the placebo group (p = .015) vs. baseline; this reduction was greater in the former group than in the latter (p = .0047; Figure 1A and F). The IL-8 (44%, p = .045), M-CSF (25%, p = .041) and IL-1Ra (36%, p = .05) levels were also decreased in PTIC group vs. baseline ( Figure 1B -F). TRAIL levels were decreased in the placebo group (14%, p = .002) vs. baseline (Figures 1E and S2) .

On days 1, 8 and 90 after the last PTIC or placebo administration, the patient percentage with oxygen saturation readings ≥92% in the PTIC and placebo groups were 90% vs. 67% (p = .007; mean oxygen saturation: 94 ± 2.4 vs. 93 ± 3.3, p = .085), 98% vs. 80% (p = .009; mean oxygen saturation; 95 ± 1.7 vs. 93 ± 2.2, p = .003) and 100% vs. 89% (p = .033; mean oxygen saturation: 95 ± 2.1 vs. 95 ± 2.3, p = .429), respectively ( Table 2) .

The Kaplan-Meier survival curve for oxygen saturations ≥92% while breathing ambient air was statistically different between groups (log-rank p = .0109; Figure 2A ). Since there were no significant differences between groups at baseline, we did not make any adjustments. The Cox regression model indicated that the hazard for meeting an oxygen saturation lower than 92% was significantly lower in the PTIC than in the placebo group (HR 0.25, Wald p value = .0384). When stratifying by age, no changes occurred. Based on the accelerated time failure model, subjects of the PTIC group reached oxygen saturations 92% or greater 2.7-fold faster than the placebo group at 3 and 8 days (p < .001 in both cases). In terms of risk, this implied that the PTIC group had a 63% lower risk for mean oxygen saturations readings below 92% (p < .001; Figure 2B ).

Symptom improvement was reported daily by every patient and compared with baseline. Symptom duration in the PTIC group was reduced by 6.1 ± 3.2 days vs. placebo ( Figure S3 and Table 2 ). .7486

Coronary artery This manuscript was published as preprint.

https: //www.medrxiv.org/content/10.1101/2021.05.12.21257133v1 O R C I D Ángel Priego-Ranero https://orcid.org/0000-0002-7801-6438 Janette Furuzawa-Carballeda https://orcid.org/0000-0001-5804-7221

Hernández-Ramírez 4

Dexamethasone in hospitalized patients with Covid-19 -preliminary report

Mediators of inflammation are down-regulated while apoptosis is up-regulated in rheumatoid arthritis synovial tissue by polymerized collagen

Effect of polymerized-type I collagen in knee osteoarthritis. I. In vitro study

Polymerized-type I collagen induces upregulation of Foxp3-expressing CD4 regulatory T cells and downregulation of IL-17-producing CD4 + T cells (Th17) cells in collagen-induced arthritis

Effect of polymerized-type I collagen in knee osteoarthritis. II. In vivo study

Polymerized-Type I Collagen down-regulates inflammation and improves clinical outcomes in patients with symptomatic knee osteoarthritis post-arthroscopic lavage. A randomized, doubleblind placebo-controlled clinical trial

Long-term effectiveness of polymerized-type I collagen intra-articular injections in patients with symptomatic knee osteoarthritis: clinical and radiographic evaluation in a cohort study

Subcutaneous administration of polymerized-type I collagen for the treatment of patients with rheumatoid arthritis. An open-label pilot trial

Polymerized-type I collagen for the treatment of patients with rheumatoid arthritis. Effect of intramuscular administration in a double-blind placebo-controlled clinical trial

Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19

At 1 day post-treatment, 3/43 subjects (7%) of the placebo group were hospitalised for 5-21 days ( Table 2 ). All patients were discharged alive, and no deaths occurred.On days 1 and 8 post-treatment with PTIC, serum levels of LDH and high sensitivity CRP (hs-CRP) decreased (52% and 73%, respectively) vs. baseline levels (p = .002 and p < .001). In the placebo group, hsCRP levels were 3% and 67% lower at 1 and 8 days compared with baseline levels ( Figure S4 and Table S3 ).At days 1 and 8 post-treatment, D-dimer levels in PTIC subjects decreased (55% and 61%, respectively); in the placebo group, D-dimer increased 42% and 32%, respectively Figure S4 and Table S3 ). No differences were detected in the other laboratory variables compared to the baseline.No serious adverse events were detected (Table S1 and S2). PTIC was safe and well-tolerated.In summary, it has been demonstrated that intramuscular PTIC treatment of symptomatic COVID-19 outpatients was useful for decreasing IP-10, IL-8 and M-CSF, all of them biomarkers of severe disease, 10 during the first week of treatment. It was associated with better oxygen saturation values when compared to placebo. Also, PTIC shortened symptom duration. On days 1 and 8 post-treatment with PTIC, a higher mean oxygen saturation value and a higher proportion of patients retaining oxygen saturation values ≥92% were observed. This could be related to decreased dyspnoea, chest pain and cough. Regarding systemic inflammation, treatment with PTIC, statistically significant lower levels of hsCRP, D-dimer and LDH, all of them identified as important biomarkers for the activity and severity of the disease, were observed. The benefit was evident in the early stage of the infection (7 days after symptom onset). PTIC was safe and well-tolerated. It did not induce liver damage, impairment of haematopoiesis or alterations in blood count. We think that treating outpatients with PTIC could potentially avoid visits to the Emergency Department and hospitalisations. As judged by symptom improvement, it could aid in preventing sequelae, such as persistent dyspnoea.

Polymerised type I collagen was donated by Aspid SA de CV. We thank Dr. Alicia Frenk-Mora, Dr. Judith González-Sánchez and Ivonne Aidé Lomelí Almanza for their valuable assistance with the organisation of patient appointments. We thank all patients involved in the study. We also thank the Triage and Emergency Departments.

The authors declare that they have no competing interests.

The funder of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.